NewAmsterdam Share Price

NewAmsterdam Share Price

NASDAQ: NAMSW | Small Cap | Healthcare
$8.82
+$8.82 (--%) Last updated on 16 Oct, 2026 | 20:07 IST
  • Performance
  • Chart
  • Fundamentals
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • About
  • Price history
  • FAQs

NewAmsterdam Stock Performance

Open
N/A
Prev. Close
N/A
Circuit Range
N/A
Day Range
N/A
Year Range
$15.14 - $28.49
Volume
N/A
Average Traded
N/A

NewAmsterdam Share Price Chart

$0.00$0.00
L
Show Current Price
H

NewAmsterdam Stock Fundamentals & Key Indicators

Market Cap
$1.05B
PE Ratio (TTM)
N/A
Dividend Yield
N/A
EPS (TTM)
N/A
Revenue (TTM)
$22.50B
Return On Equity (TTM)
-32.48%
Profit Margin
-905.87%
Debt to Equity
0.00
Quarterly Earnings Growth YoY
76.79%

NewAmsterdam Quarterly Profit & Loss

All figures in USD

ParticularsDec 2025Mar 2026Jun 2026Sep 2026
Revenue$0.03$3.04$3.70$19.16
Net Profit-$74.92-$48.44-$64.14-$17.39
Net Profit Margin-249733.33%-1593.42%-1733.51%-90.76%
Income ChangeN/A35.34%-32.41%72.89%

NewAmsterdam Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$102.69$14.09$45.56$22.50
Net Profit-$22.63-$176.94-$241.60-$203.82
Net Profit Margin-22.04%-1255.78%-530.29%-905.87%
Income ChangeN/A-681.88%-36.54%15.64%

NewAmsterdam Balance Sheet

All figures in USD Million

Particulars2025202420232022
Non Current Assets93.581.210.3189.51
Current Assets675.7863.41346.79480.7
Total Assets769.28864.62347.1570.21
Non Current Liabilities0.070.28.8112.44
Current Liabilities85.79106.9249.938.04
Total Liabilities85.85107.1258.750.48
Shareholders' Equity683.43757.5288.39519.73

NewAmsterdam Cash Flow

Annually

All figures in USD Million

Particulars2025202420232022
Operating-147.78-158.56-141.2210.67
Investing-174.92-62.85-0.02-0.22
Financing29.52659.518.91391.91

About NewAmsterdam

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

NewAmsterdam Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Oct 2026
$8.82
$8.82
-41.74%
Aug 2026
$15.14
$15.14
-19.47%
Jun 2026
$18.80
$18.80
-25.46%
May 2026
$25.22
$25.22
+13.20%
Apr 2026
$20.35
$22.28
+22.42%
Mar 2026
$18.20
$18.20
-21.48%
Feb 2026
$23.18
$23.18
+5.03%
Dec 2025
$22.07
$22.07
-22.53%
Nov 2025
$27.50
$28.49
+9.58%
Oct 2025
$18.10
$26.00
+75.79%
Sep 2025
$15.24
$14.79
+13.33%
Aug 2025
$10.41
$13.05
+19.94%

NewAmsterdam Share Price FAQs